$TYRA News

Is Tyra Biosciences (TYRA) Too Reliant On Dabogratinib Amid Renewed SURF-302 Skepticism?

Tyra Biosciences' Weak Investor Sentiment Reflects Macro Pressures, Renewed SURF-302 Concerns, BofA Says

B of A Securities Maintains Buy on Tyra Biosciences, Raises Price Target to $42

Wolfe Research Initiates Peer Perform rating on Tyra Biosciences, Inc. (TYRA)

TYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS DAY

Wolfe Research Initiates Coverage On Tyra Biosciences with Peer Perform Rating

Assessing Tyra Biosciences (TYRA) Valuation After Strong One Year Share Price Momentum

HC Wainwright & Co. Reiterates Buy on Tyra Biosciences, Maintains $45 Price Target

Tyra Biosciences, Inc. (TYRA) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Tyra Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights

Tyra Biosciences Q1 EPS $(0.64) Misses $(0.59) Estimate

Tyra Biosciences to Participate in Upcoming Investor Conferences

Guggenheim Starts Tyra Biosciences, Inc. (TYRA) at Buy on Strength of Lead Drug Dabogratinib

Tyra Biosciences Announces Appointment of Habib Dable to its Board of Directors

Guggenheim Initiates Coverage On Tyra Biosciences with Buy Rating, Announces Price Target of $54

Canaccord Genuity Initiates Coverage On Tyra Biosciences with Buy Rating, Announces Price Target of $50

A Look At Tyra Biosciences (TYRA) Valuation After $126 Million Stock Sale And Late Stage Trial Progress

Piper Sandler Maintains Overweight on Tyra Biosciences, Raises Price Target to $56

On March 4, 2026, Tyra Biosciences Agreed To Issue And Sell 4,000,000 Shares Of Common Stock To A Large Investment Management Firm At A Purchase Price Of $31.50 Per Share; Co. Expects To Receive $126.0M In Gross Proceeds Upon Settlement, Before Deducting Fees And Other Expenses Payable By It

Did Deeper Losses and Dabogratinib Progress Just Shift Tyra Biosciences' (TYRA) Investment Narrative?